本文已被：浏览 716次 下载 719次
Received:December 13, 2020 Published Online:June 20, 2021
Received:December 13, 2020 Published Online:June 20, 2021
中文摘要: 肺癌是全球常见的恶性肿瘤之一,在我国其发病率及死亡率都位居首位,非小细胞肺癌(NSCLC)占绝大多数。其中表皮生长因子受体(EGFR)基因突变是NSCLC的主要驱动基因之一,因此表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKIs)的出现,给携带EGFR基因突变的NSCLC患者治疗带来了新的生存奇迹。但一些特殊类型的EGFR基因突变如20外显子插入突变(EGFR 20ins)的患者却通常对第1代和第2代TKIs相对不敏感。目前对于EGFR 20ins的肺癌患者,还没有成熟的分子靶向药物。本文报道1例非小细胞肺癌EGFR 20ins的病例来总结探讨此类疾病的临床诊治经验。
Abstract:Lung cancer is one of the most common malignant tumors in the world. Incidence rate and mortality rate are the highest in China. Non-small cell lung cancer (NSCLC) accounts for the majority. Epidermal growth factor receptor (EGFR) gene mutation is one of the main driving genes of NSCLC. Therefore, the emergence of EGFR-(tyrosine kinase inhibitors) TKIs brings a new survival miracle to NSCLC patients with EGFR gene mutation. However, some special types of EGFR gene mutations, such as exon 20 insertion mutation (20ins), are generally not sensitive to the first and second generation TKIs. At present, there is no mature molecular targeted drug for EGFR 20ins in lung cancer patients. A case of NSCLC with EGFR 20ins was reported in this paper.
keywords: Exon 20 insertion mutation Lung cancer Targeted therapy Epidermal growth factor receptorFund program:General
文章编号： 中图分类号： 文献标志码：B
基金项目:陕西省自然科学基金面上项目(2019JM-563)
| Author Name | Affiliation |
| XUE Xin*, YUE Qing-fang, YAO Jun-tao | *Xi'an Medical University, Xi'an, Shaanxi 710021, China |
| 岳青芳2 | 2.陕西省人民医院,陕西 西安 710068 |
| 姚俊涛3 | 3.西安交通大学附属陕西省肿瘤医院,陕西 西安 710061 |
| Author Name | Affiliation |
| XUE Xin*, YUE Qing-fang, YAO Jun-tao | *Xi'an Medical University, Xi'an, Shaanxi 710021, China |
| 岳青芳2 | 2.陕西省人民医院,陕西 西安 710068 |
| 姚俊涛3 | 3.西安交通大学附属陕西省肿瘤医院,陕西 西安 710061 |
引用文本：